|
USRE43932E1
(en)
|
1997-07-18 |
2013-01-15 |
Novartis Ag |
Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
|
|
CO4940418A1
(es)
*
|
1997-07-18 |
2000-07-24 |
Novartis Ag |
Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
|
|
ITMI992711A1
(it)
*
|
1999-12-27 |
2001-06-27 |
Novartis Ag |
Composti organici
|
|
US7087608B2
(en)
|
2000-03-03 |
2006-08-08 |
Robert Charles Atkins |
Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
|
|
DK1332137T3
(da)
*
|
2000-10-27 |
2006-07-17 |
Novartis Ag |
Behandling af gastrointestinale stromale tumorer
|
|
LT3143995T
(lt)
|
2001-02-19 |
2019-01-25 |
Novartis Ag |
Rapamicino darinys, skirtas plaučių vėžio gydymui
|
|
KR100848197B1
(ko)
*
|
2001-02-27 |
2008-07-24 |
노파르티스 아게 |
신호 전달 억제제 및 에포틸론 유도체를 포함하는 배합물
|
|
GB0108606D0
(en)
*
|
2001-04-05 |
2001-05-23 |
Novartis Ag |
Organic compounds
|
|
AU2005246965B2
(en)
*
|
2001-05-16 |
2008-04-17 |
Novartis Ag |
Combination comprising N-{5-[4(4-methyl-piperazino-methyl)-bezoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
|
|
EP1704863A3
(en)
*
|
2001-05-16 |
2010-11-24 |
Novartis AG |
Combination comprising N-5-4-(4-Methyl-Piperazino-Methyl-)Benzoyla Mido]-2-Methylphenyl -4-(3-Pyridyl)-2Phyrimidine-amine and a chemotherapeutic agent
|
|
PL368068A1
(en)
*
|
2001-05-16 |
2005-03-21 |
Novartis Ag |
Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
|
|
CA2450473C
(en)
|
2001-06-14 |
2011-11-15 |
The Regents Of The University Of California |
Mutations in the bcr-abl tyrosine kinase associated with resistance to sti-571
|
|
EP1408978A4
(en)
*
|
2001-06-21 |
2005-07-13 |
Ariad Pharma Inc |
NOVEL PHENYLAMINO-PYRIMIDINES AND THEIR USE
|
|
DK1401415T3
(da)
|
2001-06-29 |
2006-10-16 |
Ab Science |
Anvendelse af N-phenyl-2-pyrimidinamin-derivater til behandling af inflammatoriske sygdomme
|
|
EP1401416B1
(en)
|
2001-06-29 |
2006-10-25 |
AB Science |
Use of c-kit inhibitors for treating inflammatory bowel diseases (ibd)
|
|
JP2005500041A
(ja)
*
|
2001-06-29 |
2005-01-06 |
アブ サイエンス |
強力で選択的かつ非毒性のｃ−ｋｉｔ阻害剤
|
|
EP1401413B1
(en)
|
2001-06-29 |
2006-11-22 |
AB Science |
Use of tyrosine kinase inhibitions for treating allergic diseases
|
|
CN1523991A
(zh)
|
2001-08-10 |
2004-08-25 |
��˹��ŵ�� |
单独的c-Src抑制剂或其与STI571的组合用于治疗白血病的用途
|
|
GB0120690D0
(en)
|
2001-08-24 |
2001-10-17 |
Novartis Ag |
Organic compounds
|
|
US20060204459A1
(en)
*
|
2001-09-20 |
2006-09-14 |
Alain Moussy |
Use of tyrosine inhibitors for whitening human skin and treating melanocyted dysfunction associated diseases
|
|
PT2017335E
(pt)
|
2001-10-05 |
2011-03-02 |
Novartis Ag |
Domínios da cinase abl mutados
|
|
US7045523B2
(en)
|
2001-10-18 |
2006-05-16 |
Novartis Ag |
Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and telomerase inhibitor
|
|
PL374315A1
(en)
*
|
2001-10-25 |
2005-10-03 |
Wisconsin Alumni Research Foundation |
Vascular stent or graft coated or impregnated with protein tyrosine kinase inhibitors and method of using same
|
|
GB0127922D0
(en)
*
|
2001-11-21 |
2002-01-16 |
Novartis Ag |
Organic compounds
|
|
GB0201508D0
(en)
|
2002-01-23 |
2002-03-13 |
Novartis Ag |
Organic compounds
|
|
AU2007201056B2
(en)
*
|
2002-01-28 |
2010-06-10 |
Hyks-Instituutti Oy |
Treatment of rheumatoid arthritis using imatinib
|
|
GB0201882D0
(en)
*
|
2002-01-28 |
2002-03-13 |
Novartis Ag |
Organic compounds
|
|
GB0202873D0
(en)
*
|
2002-02-07 |
2002-03-27 |
Novartis Ag |
Organic compounds
|
|
AU2003209521A1
(en)
*
|
2002-02-22 |
2003-09-09 |
Oregon Health And Science University (Ohsu) |
Use of 4-(4-methylpiperazin-1-ylmethyl)-n(4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl)-benzamide for treating seminomas
|
|
BR0308053A
(pt)
*
|
2002-02-28 |
2004-12-28 |
Novartis Ag |
Stents revestidos com n-{5-[4-(4-metil-piperazino-metil)-benzoilamido]-2-metil fenil}-4-(3-piridil)-2-pirimidina-amina
|
|
ES2274234T3
(es)
*
|
2002-03-15 |
2007-05-16 |
Novartis Ag |
4-(4-metilpiperazin-1-ilmetil)-n-(4-metil-3(4-piridin-3-il)pirimidin -2-ilamino)fenil)-benzamida para el tratamiento de enfermedades mediadas por ang ii.
|
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
|
US20060128720A1
(en)
*
|
2002-03-21 |
2006-06-15 |
Kufe Donald W |
Inhibition of cell death responses induced by oxidative stress
|
|
AU2003216573A1
(en)
*
|
2002-04-16 |
2003-10-27 |
Issam Moussa |
Drug eluting vascular stent and method of treating hyperproliferative vascular disease
|
|
AU2007201830C1
(en)
*
|
2002-04-23 |
2017-09-07 |
Novartis Pharma Ag |
High drug load tablet
|
|
GB0209265D0
(en)
*
|
2002-04-23 |
2002-06-05 |
Novartis Ag |
Organic compounds
|
|
PL372103A1
(en)
|
2002-05-16 |
2005-07-11 |
Novartis Ag |
Use of edg receptor binding agents in cancer
|
|
AU2003295320A1
(en)
*
|
2002-06-26 |
2004-04-08 |
The Ohio State University Research Foundation |
The method for reducing inflammation using sti-571 or its salt
|
|
AU2003246100A1
(en)
*
|
2002-06-28 |
2004-01-19 |
Nippon Shinyaku Co., Ltd. |
Amide derivative
|
|
BR0312242A
(pt)
*
|
2002-06-28 |
2005-04-12 |
Univ Tulane |
4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil]-benzamida para o tratamento da fibrose pulmonar
|
|
AU2003252047A1
(en)
*
|
2002-07-18 |
2004-02-09 |
Medtronic Ave Inc. |
Medical devices comprising a protein-tyrosine kinase inhibitor to inhibit restonosis
|
|
EP1530474A1
(en)
*
|
2002-07-19 |
2005-05-18 |
Ludwig Institute For Cancer Research |
Enhancing the effect of radioimmunotherapy in the treatment of tumors
|
|
WO2004009087A1
(en)
*
|
2002-07-24 |
2004-01-29 |
University Of Cincinnati |
4-4(methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating mutated-ret kinase associated diseases
|
|
CA2498982A1
(en)
*
|
2002-07-24 |
2004-01-29 |
Novartis Ag |
4-(4-methylpiperazin-1-ylmethyl)-n-[4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating anaplastic thyroid cancer
|
|
EP1542989B1
(en)
*
|
2002-07-31 |
2007-04-18 |
Critical Outcome Technologies, Inc. |
Protein tyrosine kinase inhibitors
|
|
US8450302B2
(en)
|
2002-08-02 |
2013-05-28 |
Ab Science |
2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
|
|
KR101036866B1
(ko)
|
2002-08-02 |
2011-05-25 |
에이비 사이언스 |
2-(3-아미노아릴)아미노-4-아릴-티아졸 및 ｃ-ｋｉｔ억제제로서의 이의 용도
|
|
CA2439440A1
(en)
|
2002-09-05 |
2004-03-05 |
Emory University |
Treatment of tuberous sclerosis associated neoplasms
|
|
ATE380810T1
(de)
*
|
2002-10-09 |
2007-12-15 |
Critical Outcome Technologies |
Protein-tyrosine-kinase-inhibitoren
|
|
GB0224455D0
(en)
*
|
2002-10-21 |
2002-11-27 |
Novartis Ag |
Organic compounds
|
|
JP4942297B2
(ja)
*
|
2002-10-25 |
2012-05-30 |
ジ アドミニストレイターズ オブ ザ チューレン エデュケイショナル ファンド |
肺高血圧症の処置を目的としたｎ−｛５−［４−（４−メチルピペラジノメチル）−ベンゾイルアミド］−２−メチルフェニル｝−４−（３−ピリジル）−２−ピリジン−アミンの使用
|
|
US7094785B1
(en)
|
2002-12-18 |
2006-08-22 |
Cornell Research Foundation, Inc. |
Method of treating polycythemia vera
|
|
GB2398565A
(en)
|
2003-02-18 |
2004-08-25 |
Cipla Ltd |
Imatinib preparation and salts
|
|
RU2325193C2
(ru)
*
|
2003-04-04 |
2008-05-27 |
Бэйко Тек Лимитед |
Сосудистый стент
|
|
AU2003232650A1
(en)
|
2003-05-06 |
2004-11-26 |
Il Yang Pharm Co., Ltd. |
N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
|
|
CL2004001120A1
(es)
|
2003-05-19 |
2005-04-15 |
Irm Llc |
Compuestos derivados de amina sustituidas con heterociclos, inmunosupresores; composicion farmaceutica; y uso para tratar enfermedades mediadas por interacciones de linfocito, tales como enfermedades autoinmunes, inflamatorias, infecciosas, cancer.
|
|
MY150088A
(en)
|
2003-05-19 |
2013-11-29 |
Irm Llc |
Immunosuppressant compounds and compositions
|
|
GB0312086D0
(en)
*
|
2003-05-27 |
2003-07-02 |
Novartis Ag |
Organic compounds
|
|
JP4776537B2
(ja)
*
|
2003-05-27 |
2011-09-21 |
ロベルト・ペール・ヘーガークヴィスト |
糖尿病処置のためのチロシンキナーゼ阻害剤の使用
|
|
AU2003237596A1
(en)
|
2003-06-02 |
2005-01-21 |
Hetero Drugs Limited |
Novel polymorphs of imatinib mesylate
|
|
JP2006526652A
(ja)
*
|
2003-06-03 |
2006-11-24 |
ベス・イスラエル・ディーコニス・メディカル・センター |
血管狭窄を治療するための方法及び化合物
|
|
CN100467064C
(zh)
*
|
2003-09-19 |
2009-03-11 |
诺瓦提斯公司 |
伊马替尼和米哚妥林在制备治疗胃肠道基质肿瘤药物中的应用
|
|
BRPI0415467A
(pt)
|
2003-10-23 |
2006-12-19 |
Ab Science |
compostos de 2-aminoariloxazol para o tratamento de doenças
|
|
RU2362562C2
(ru)
|
2003-11-18 |
2009-07-27 |
Новартис Аг |
Ингибиторы мутантной формы киназы kit
|
|
WO2005063720A1
(ja)
*
|
2003-12-25 |
2005-07-14 |
Nippon Shinyaku Co., Ltd. |
アミド誘導体及び医薬
|
|
AR047530A1
(es)
|
2004-02-04 |
2006-01-25 |
Novartis Ag |
Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-(4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil)-benzamida
|
|
HUE028884T2
(hu)
*
|
2004-02-11 |
2017-01-30 |
Natco Pharma Ltd |
Imatinib-mezilát új polimorfikus formája és folyamat annak elõállítására
|
|
CN1309719C
(zh)
*
|
2004-02-18 |
2007-04-11 |
陈国庆 |
苯氨基嘧啶衍生物及其用途
|
|
UA84462C2
(ru)
*
|
2004-04-02 |
2008-10-27 |
Институт Фармацевтични |
Полиморфные модификации кислотно-аддитивных солей иматиниба с метансульфоновой кислотой
|
|
TWI417092B
(zh)
|
2004-04-07 |
2013-12-01 |
Novartis Ag |
Ｉａｐ抑制劑
|
|
GB0512324D0
(en)
|
2005-06-16 |
2005-07-27 |
Novartis Ag |
Organic compounds
|
|
RU2007103703A
(ru)
*
|
2004-07-01 |
2008-08-10 |
Дзе Недзеландз Кэнсе Инститьют (Nl) |
Комбинация, включающая ингибитор бррм (белка резистентности рака молочной железы) и 4-(4-метилпиперазин-1-илметил)-n-(4-метил-3-(4-пиридин-3-ил)пиримидин-2-иламино)фенил)-бензамид
|
|
KR101348625B1
(ko)
|
2004-09-02 |
2014-01-07 |
씨아이피엘에이 엘티디. |
이매티닙 메실레이트의 안정한 결정형 및 그의 제조방법
|
|
JP5184887B2
(ja)
|
2004-09-09 |
2013-04-17 |
ナトコ ファーマ リミテッド |
ｂｃｒ−ａｂｌキナーゼの阻害剤としての新規フェニルアミノピリミジン誘導体
|
|
US8735415B2
(en)
|
2004-09-09 |
2014-05-27 |
Natco Pharma Limited |
Acid addition salts of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
|
|
WO2006048890A1
(en)
*
|
2004-11-04 |
2006-05-11 |
Sun Pharmaceutical Industries Limited |
Imatinib mesylate crystal form and process for preparation thereof
|
|
WO2006054314A1
(en)
*
|
2004-11-17 |
2006-05-26 |
Natco Pharma Limited |
Polymorphic forms of imatinib mesylate
|
|
AU2005321946B2
(en)
|
2004-12-23 |
2012-08-16 |
Deciphera Pharmaceuticals, Llc |
Enzyme modulators and treatments
|
|
JP5204643B2
(ja)
|
2005-04-04 |
2013-06-05 |
アブ サイエンス |
置換オキサゾール誘導体、およびチロシンキナーゼ阻害薬としてのそれらの使用
|
|
CN103638028A
(zh)
|
2005-05-02 |
2014-03-19 |
诺瓦提斯公司 |
嘧啶基氨基苯甲酰胺衍生物用于治疗全身性肥大细胞增多症的应用
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
ES2339593T3
(es)
*
|
2005-06-03 |
2010-05-21 |
Novartis Ag |
Combinacion de compuestos de pirimidilaminobenzamida e imatinib para tratar o prevenir enfermedades proliferativas.
|
|
GT200600316A
(es)
|
2005-07-20 |
2007-04-02 |
|
Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
|
|
KR100674813B1
(ko)
|
2005-08-05 |
2007-01-29 |
일양약품주식회사 |
Ｎ-페닐-2-피리미딘-아민 유도체 및 그의 제조방법
|
|
ES2334933T3
(es)
*
|
2005-08-15 |
2010-03-17 |
Siegfried Generics International Ag |
Comprimido recubierto o granulado que contiene una piridilpirimidina.
|
|
JP2009506014A
(ja)
|
2005-08-26 |
2009-02-12 |
ノバルティス アクチエンゲゼルシャフト |
イマチニブメシレートのデルタおよびイプシロン結晶形
|
|
JP2009516671A
(ja)
|
2005-11-21 |
2009-04-23 |
ノバルティス アクチエンゲゼルシャフト |
ｍＴＯＲ阻害剤を使用する神経内分泌腫瘍処置
|
|
CN102351842B
(zh)
*
|
2005-11-25 |
2014-07-23 |
诺华股份有限公司 |
甲磺酸伊马替尼的f、g、h、i 和k晶形
|
|
GB0605120D0
(en)
|
2006-03-14 |
2006-04-26 |
Novartis Ag |
Organic Compounds
|
|
BRPI0709750A2
(pt)
|
2006-04-05 |
2011-07-26 |
Novartis Ag |
combinaÇÕes de agentes terapÊuticos para tratamento de cÂncer
|
|
US20090233905A1
(en)
|
2006-04-05 |
2009-09-17 |
Gregory Peter Burke |
Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer
|
|
US8067421B2
(en)
*
|
2006-04-27 |
2011-11-29 |
Sicor Inc. |
Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
|
|
US7977348B2
(en)
*
|
2006-04-27 |
2011-07-12 |
Sicor Inc. |
Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
|
|
BRPI0702877A2
(pt)
*
|
2006-04-27 |
2015-07-07 |
Ivax Pharmaceuticals S R O E Teva Pharmaceutical Usa Inc |
Formas polimórficas de mesilato de imatinib, processo para o novo preparo de novas formas cristalinas, amorfas e forma alfa, composições farmacêuticas correlatas, seus processos de preparo e uso
|
|
US20060223816A1
(en)
*
|
2006-05-08 |
2006-10-05 |
Chemagis Ltd. |
Imatinib mesylate alpha form and production process therefor
|
|
NZ572299A
(en)
|
2006-05-09 |
2010-07-30 |
Novartis Ag |
Combination comprising a substituted 3,5-diphenyl-1,2,4-triazole and a platinum compound and use thereof
|
|
US20060223817A1
(en)
*
|
2006-05-15 |
2006-10-05 |
Chemagis Ltd. |
Crystalline imatinib base and production process therefor
|
|
WO2008004945A1
(en)
*
|
2006-07-04 |
2008-01-10 |
Astrazeneca Ab |
Novel crystalline forms i and ii
|
|
WO2008004944A1
(en)
*
|
2006-07-04 |
2008-01-10 |
Astrazeneca Ab |
Novel crystalline form ii
|
|
US8246966B2
(en)
|
2006-08-07 |
2012-08-21 |
University Of Georgia Research Foundation, Inc. |
Trypanosome microsome system and uses thereof
|
|
US20090324718A1
(en)
*
|
2006-09-01 |
2009-12-31 |
Ilan Zalit |
Imatinib compositions
|
|
BRPI0717099A2
(pt)
|
2006-09-22 |
2013-10-15 |
Novartis Ag |
Método de otimização do tratamento de leucemia filadélfia-positiva com inibidores de abl tirosina quinase
|
|
CA2664378A1
(en)
|
2006-09-29 |
2008-04-03 |
Novartis Ag |
Pyrazolopyrimidines as pi3k lipid kinase inhibitors
|
|
WO2008057291A2
(en)
*
|
2006-10-26 |
2008-05-15 |
Sicor Inc. |
Crystalline and amorphous imatinib base, imatinib mesylate- and processes for preparation thereof
|
|
EP2009008A1
(en)
|
2006-10-26 |
2008-12-31 |
Sicor, Inc. |
Imatinib base, and imatinib mesylate and processes for preparation thereof
|
|
WO2008070350A2
(en)
|
2006-10-27 |
2008-06-12 |
The Board Of Regents Of The University Of Texas System |
Methods and compositions related to wrapping of dehydrons
|
|
KR20090094815A
(ko)
*
|
2006-11-09 |
2009-09-08 |
애보트 게엠베하 운트 콤파니 카게 |
티로신 키나아제 억제제의 경구 투여를 위한 약제 투여형
|
|
EP1920767A1
(en)
*
|
2006-11-09 |
2008-05-14 |
Abbott GmbH & Co. KG |
Melt-processed imatinib dosage form
|
|
EP2088863A2
(en)
|
2006-11-22 |
2009-08-19 |
University Of Georgia Research Foundation, Inc. |
Tyrosine kinase inhibitors as anti-kinetolastid and anti-apicomplexan agents
|
|
WO2008083491A1
(en)
|
2007-01-11 |
2008-07-17 |
Critical Outcome Technologies Inc. |
Compounds and method for treatment of cancer
|
|
WO2008093246A2
(en)
|
2007-02-02 |
2008-08-07 |
Vegenics Limited |
Vegf receptor antagonist for treating organ transplant alloimmunity and arteriosclerosis
|
|
KR100799821B1
(ko)
*
|
2007-02-05 |
2008-01-31 |
동화약품공업주식회사 |
신규한 이마티닙 캠실레이트 및 그의 제조방법
|
|
PL2366703T3
(pl)
*
|
2007-02-13 |
2015-02-27 |
Ab Science |
Postać polimorficzna pochodnej 2-amino-(nitroarylo)-tiazolu
|
|
EP2120900A2
(en)
|
2007-02-15 |
2009-11-25 |
Novartis AG |
Combination of lbh589 with other therapeutic agents for treating cancer
|
|
CN101323629B
(zh)
*
|
2007-02-16 |
2011-08-17 |
江苏正大天晴药业股份有限公司 |
4-{6-[5-(2-氯-6-甲基苯胺甲酰基)-噻唑-2-氨基]-2-甲基嘧啶-4}-哌嗪-1-甲基磷酸二乙酯
|
|
US20100087444A1
(en)
*
|
2007-03-12 |
2010-04-08 |
Dr. Reddy's Laboratories Ltd. |
Imatinib mesylate
|
|
US20080234286A1
(en)
*
|
2007-03-20 |
2008-09-25 |
Chemagis Ltd. |
Stable amorphous imatinib mesylate and production process therefor
|
|
US7550591B2
(en)
*
|
2007-05-02 |
2009-06-23 |
Chemagis Ltd. |
Imatinib production process
|
|
WO2008136010A1
(en)
*
|
2007-05-07 |
2008-11-13 |
Natco Pharma Limited |
A process for the preparation of highly pure imatinib base
|
|
WO2008150481A2
(en)
*
|
2007-05-29 |
2008-12-11 |
Sicor Inc. |
Processes for the preparation of crystalline form beta of imatinib mesylate
|
|
PL2305263T3
(pl)
|
2007-06-07 |
2012-12-31 |
Novartis Ag |
Stabilizowane amorficzne formy mesylanu imatinibu
|
|
EP2081556A1
(en)
*
|
2007-09-25 |
2009-07-29 |
Teva Pharmaceutical Industries Ltd. |
Stable imatinib compositions
|
|
US20090082361A1
(en)
*
|
2007-09-26 |
2009-03-26 |
Protia, Llc |
Deuterium-enriched imatinib
|
|
WO2009048947A1
(en)
*
|
2007-10-09 |
2009-04-16 |
Board Of Regents, The University Of Texas System |
Methods of treatment of opioid tolerance, physical dependence, pain, and addiction with inhibitors of certain growth factor receptors
|
|
WO2009079797A1
(en)
*
|
2007-12-26 |
2009-07-02 |
Critical Outcome Technologies, Inc. |
Compounds and method for treatment of cancer
|
|
MX2010010525A
(es)
|
2008-03-24 |
2010-10-25 |
Novartis Ag |
Inhibidores de metaloproteasa de matriz basados en aril-sulfonamida.
|
|
EA019033B1
(ru)
|
2008-03-26 |
2013-12-30 |
Новартис Аг |
Ингибиторы дезацетилазы в, основанные на гидроксамате
|
|
US9273077B2
(en)
|
2008-05-21 |
2016-03-01 |
Ariad Pharmaceuticals, Inc. |
Phosphorus derivatives as kinase inhibitors
|
|
DK2300013T3
(en)
|
2008-05-21 |
2017-12-04 |
Ariad Pharma Inc |
PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS
|
|
CN101584696A
(zh)
|
2008-05-21 |
2009-11-25 |
上海艾力斯医药科技有限公司 |
包含喹唑啉衍生物的组合物及制备方法、用途
|
|
CA2727737C
(en)
|
2008-06-27 |
2016-08-23 |
Indiana University Research And Technology Corporation |
Materials and methods for suppressing and/or treating neurofibroma and related tumors
|
|
DE102008031037A1
(de)
|
2008-06-30 |
2009-12-31 |
Dömling, Alexander, Priv.-Doz. Dr. |
Gleevec zur Anwedung in der Organtransplantation
|
|
EP3023426A1
(en)
|
2008-07-17 |
2016-05-25 |
Critical Outcome Technologies, Inc. |
Thiosemicarbazone inhibitor compounds and cancer treatment methods
|
|
WO2010019557A1
(en)
*
|
2008-08-12 |
2010-02-18 |
Concert Pharmaceuticals Inc. |
N-phenyl-2-pyrimidineamine derivatives
|
|
ES2704986T3
(es)
|
2008-10-16 |
2019-03-21 |
Celator Pharmaceuticals Inc |
Combinaciones de una camptotecina liposomal soluble en agua con cetuximab o bevacizumab
|
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
|
EP2186514B1
(en)
*
|
2008-11-14 |
2016-06-29 |
Kinki University |
Treatment of Malignant Peripheral Nerve Sheath Tumors
|
|
EP2370078A1
(en)
|
2008-12-01 |
2011-10-05 |
Novartis AG |
Method of optimizing the treatment of philadelphia-positive leukemia with imatinib mesylate
|
|
LT2676953T
(lt)
|
2008-12-18 |
2017-06-26 |
Novartis Ag |
1-[4-[1-(4-cikloheksil-3 -trifluormetil-benziloksiimino)-etil]-2-etil-benzil]-azetidin-3-karboksilinės rūgšties hemifumarato druska, skirta panaudoti gydant limfocitų tarpininkavimo ligas
|
|
EP2379499B1
(en)
|
2008-12-18 |
2014-04-09 |
Novartis AG |
Hydrochloride salt of 1-(4-(1-((E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl)-2-ethyl-benzyl)-azetidine-3-carboxylic acid
|
|
MX2011006610A
(es)
|
2008-12-18 |
2011-06-30 |
Novartis Ag |
Nueva forma polimorfica de acido 1-(4-{l-[(e)-4-ciclohexil-3 -trifluorometil-benciloxi-imino]-etil)-2-etil-bencil)-azetidin-3 carboxilico.
|
|
WO2010083617A1
(en)
|
2009-01-21 |
2010-07-29 |
Oncalis Ag |
Pyrazolopyrimidines as protein kinase inhibitors
|
|
JP2012516345A
(ja)
|
2009-01-29 |
2012-07-19 |
ノバルティス アーゲー |
星細胞腫治療用置換ベンゾイミダゾール
|
|
UA103918C2
(en)
|
2009-03-02 |
2013-12-10 |
Айерем Элелси |
N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
|
|
US8530492B2
(en)
|
2009-04-17 |
2013-09-10 |
Nektar Therapeutics |
Oligomer-protein tyrosine kinase inhibitor conjugates
|
|
RU2563631C2
(ru)
|
2009-04-28 |
2015-09-20 |
Дайити Санкио Компани, Лимитед |
Новые кристаллы сольватов
|
|
US20100330130A1
(en)
*
|
2009-05-22 |
2010-12-30 |
Actavis Group Ptc Ehf |
Substantially pure imatinib or a pharmaceutically acceptable salt thereof
|
|
TW201102068A
(en)
*
|
2009-06-02 |
2011-01-16 |
Novartis Ag |
Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
|
|
EA021011B1
(ru)
|
2009-06-26 |
2015-03-31 |
Новартис Аг |
1,3-ДИЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ ИМИДАЗОЛИДИН-2-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ Cyp 17
|
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
|
KR20120089643A
(ko)
|
2009-08-12 |
2012-08-13 |
노파르티스 아게 |
헤테로시클릭 히드라존 화합물, 및 암 및 염증을 치료하기 위한 그의 용도
|
|
US9085560B2
(en)
|
2009-08-17 |
2015-07-21 |
Intellikine, Inc. |
Heterocyclic compounds and uses thereof
|
|
JP5775871B2
(ja)
|
2009-08-20 |
2015-09-09 |
ノバルティス アーゲー |
ヘテロ環式オキシム化合物
|
|
EA201200321A1
(ru)
|
2009-08-26 |
2012-09-28 |
Новартис Аг |
Тетразамещенные гетероарильные соединения и их применение в качестве модуляторов mdm2 и/или mdm4
|
|
CZ2009570A3
(cs)
|
2009-08-26 |
2011-03-09 |
Zentiva, K. S. |
Príprava, stabilizace a využití polymorfu imatinib mesylátu pro vývoj lékových forem
|
|
KR20120093867A
(ko)
|
2009-09-10 |
2012-08-23 |
아이알엠 엘엘씨 |
비시클릭 헤테로아릴의 에테르 유도체
|
|
WO2011039782A1
(en)
*
|
2009-09-29 |
2011-04-07 |
Ind-Swift Laboratories Limited |
Processes for preparing imatinib and pharmaceutically acceptable salts thereof
|
|
PL389357A1
(pl)
|
2009-10-22 |
2011-04-26 |
Tomasz Koźluk |
Sole imatinibu z pochodnymi kwasów winowych i sposób ich wytwarzania
|
|
MX2012005293A
(es)
|
2009-11-04 |
2012-06-19 |
Novartis Ag |
Derivados de sulfonamida heterociclicos utiles como inhibidores de mek.
|
|
MX2012005987A
(es)
|
2009-11-23 |
2012-06-25 |
Cerulean Pharma Inc |
Polimeros a base de ciclodextrina para administracion terapeutica.
|
|
JP2013512215A
(ja)
|
2009-11-25 |
2013-04-11 |
ノバルティス アーゲー |
二環式ヘテロアリールのベンゼン縮合６員酸素含有ヘテロ環誘導体
|
|
EP2509964B1
(en)
|
2009-12-08 |
2014-04-30 |
Novartis AG |
Heterocyclic sulfonamide derivatives
|
|
CU24130B1
(es)
|
2009-12-22 |
2015-09-29 |
Novartis Ag |
Isoquinolinonas y quinazolinonas sustituidas
|
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
|
WO2011090940A1
(en)
|
2010-01-19 |
2011-07-28 |
Cerulean Pharma Inc. |
Cyclodextrin-based polymers for therapeutic delivery
|
|
WO2011095835A1
(en)
|
2010-02-02 |
2011-08-11 |
Actavis Group Ptc Ehf |
Highly pure imatinib or a pharmaceutically acceptable salt thereof
|
|
BR112012020491A2
(pt)
|
2010-02-15 |
2017-10-10 |
Reliance Life Sciences Pvt Ltd |
processo para a preparação de forma alfa de mesilato de imatinib.
|
|
PL390611A1
(pl)
|
2010-03-04 |
2011-09-12 |
Tomasz Koźluk |
Sposób otrzymywania polimorficznej formy alfa i nowa forma polimorficzna mesylanu imatinibu
|
|
WO2011114337A1
(en)
|
2010-03-15 |
2011-09-22 |
Natco Pharma Limited |
Process for the preparation of highly pure crystalline imatinib base
|
|
WO2011119995A2
(en)
|
2010-03-26 |
2011-09-29 |
Cerulean Pharma Inc. |
Formulations and methods of use
|
|
EP3235818A3
(en)
|
2010-04-01 |
2018-03-14 |
Critical Outcome Technologies, Inc. |
Compounds for the treatment of hiv
|
|
US8609842B2
(en)
|
2010-04-23 |
2013-12-17 |
Fujian South Pharmaceutical Co., Ltd. |
Method for synthesizing Imatinib
|
|
EP2382976A1
(en)
|
2010-04-30 |
2011-11-02 |
Hiroshima University |
Use of pdgf-r inhibitors for the treatment of lymph node metastasis of gastric cancer
|
|
WO2011158255A1
(en)
*
|
2010-06-16 |
2011-12-22 |
Aptuit Laurus Private Limited |
Process for preparation of stable imatintb mesylate alpha form
|
|
EA022094B1
(ru)
*
|
2010-06-16 |
2015-10-30 |
Такеда Фармасьютикал Компани Лимитед |
Кристаллическая форма амидного соединения
|
|
CN102947274A
(zh)
|
2010-06-17 |
2013-02-27 |
诺瓦提斯公司 |
联苯基取代的1,3-二氢-苯并咪唑-2-亚基胺衍生物
|
|
US20130085161A1
(en)
|
2010-06-17 |
2013-04-04 |
Novartis Ag |
Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
|
|
EP2582689B1
(en)
|
2010-06-18 |
2017-03-01 |
KRKA, D.D., Novo Mesto |
New polymorphic form of imatinib base and preparation of salts thereof
|
|
UA112517C2
(uk)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
Тетрагідропіридопіримідинові похідні
|
|
RU2013110058A
(ru)
|
2010-08-11 |
2014-09-20 |
Синтон Б.В. |
Фармацевтический гранулят, содержащий иматиниба мезилат
|
|
TR201007005A2
(tr)
|
2010-08-23 |
2011-09-21 |
Mustafa Nevzat İlaç Sanayi̇i̇ A.Ş. |
İmatinib baz üretim yöntemi
|
|
RU2456280C2
(ru)
*
|
2010-08-27 |
2012-07-20 |
Общество с ограниченной ответственностью "Химфармресурс" |
Кристаллическая n-модификация 4-[(4-метил-1-пиперазинил)метил]-n-[4-метил-3-[[4-(3-пиридинил)-2-пиримидинил]-амино]-фенил] бензамида метансульфоната, способ ее получения и фармацевтическая композиция на ее основе
|
|
WO2012027716A1
(en)
|
2010-08-27 |
2012-03-01 |
Collabrx, Inc. |
Method to treat melanoma in braf inhibitor-resistant subjects
|
|
JP2013537210A
(ja)
|
2010-09-16 |
2013-09-30 |
ノバルティス アーゲー |
１７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤
|
|
AR083878A1
(es)
|
2010-11-15 |
2013-03-27 |
Boehringer Ingelheim Int |
Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
|
|
CN102477031B
(zh)
|
2010-11-30 |
2015-07-15 |
浙江九洲药业股份有限公司 |
一种甲磺酸伊马替尼α晶型的制备方法
|
|
TR201010618A2
(tr)
|
2010-12-20 |
2012-07-23 |
Bi̇lgi̇ç Mahmut |
İmatinib içeren bir oral dozaj formu ve bu oral dozaj formunun üretimi
|
|
BR112013015449A2
(pt)
|
2010-12-21 |
2016-09-20 |
Novartis Ag |
compostos de bi-heteroarila como inibidores de vps23
|
|
WO2012090221A1
(en)
|
2010-12-29 |
2012-07-05 |
Cadila Healthcare Limited |
Novel salts of imatinib
|
|
EP2673277A1
(en)
|
2011-02-10 |
2013-12-18 |
Novartis AG |
[1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
|
CN102146073A
(zh)
*
|
2011-02-23 |
2011-08-10 |
江苏先声药物研究有限公司 |
一种伊玛替尼甲烷磺酸盐α晶型新的制备方法
|
|
WO2012116237A2
(en)
|
2011-02-23 |
2012-08-30 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
|
CN102649785B
(zh)
*
|
2011-02-23 |
2015-08-19 |
江苏先声药物研究有限公司 |
一种伊玛替尼甲烷磺酸盐β晶型的制备方法
|
|
AU2012225693A1
(en)
|
2011-03-04 |
2013-09-19 |
Newgen Therapeutics, Inc. |
Alkyne substituted quinazoline compound and methods of use
|
|
US20130338152A1
(en)
|
2011-03-08 |
2013-12-19 |
Irm Llc |
Fluorophenyl bicyclic heteroaryl compounds
|
|
PL394169A1
(pl)
|
2011-03-09 |
2012-09-10 |
Adamed Spółka Z Ograniczoną Odpowiedzialnością |
Kompozycja farmaceutyczna metanosulfonianu imatinibu do napełniania jednostkowych postaci dawkowania oraz sposób jej wytwarzania
|
|
JP2014509642A
(ja)
|
2011-03-31 |
2014-04-21 |
アイエヌディー−スイフト ラボラトリーズ リミテッド |
イマチニブ及びそのメシル酸塩の生成のための改良方法
|
|
EA023064B1
(ru)
|
2011-04-28 |
2016-04-29 |
Новартис Аг |
ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ
|
|
WO2012151561A1
(en)
|
2011-05-04 |
2012-11-08 |
Ariad Pharmaceuticals, Inc. |
Compounds for inhibiting cell proliferation in egfr-driven cancers
|
|
WO2012155339A1
(zh)
|
2011-05-17 |
2012-11-22 |
江苏康缘药业股份有限公司 |
4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
|
|
US9945862B2
(en)
|
2011-06-03 |
2018-04-17 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
|
BR112013031201A2
(pt)
|
2011-06-09 |
2017-01-31 |
Novartis Ag |
derivados de sulfonamida heterocíclicos, composição farmacêutica os compreendendo, uso, processo para a fabricação de (r)-n-(4,5-difluoro-6-((2-fluoro-4-iodofenil)amino)benzofuran-7-il)-1-(2,3-di-idroxipropil)ciclopropano-5 1-sulfonamida e kit
|
|
EP2721007B1
(en)
|
2011-06-20 |
2015-04-29 |
Novartis AG |
Cyclohexyl isoquinolinone compounds
|
|
EP2721008B1
(en)
|
2011-06-20 |
2015-04-29 |
Novartis AG |
Hydroxy substituted isoquinolinone derivatives as p53 (mdm2 or mdm4) inhibitors
|
|
US9750700B2
(en)
|
2011-06-22 |
2017-09-05 |
Natco Pharma Limited |
Imatinib mesylate oral pharmaceutical composition and process for preparation thereof
|
|
EA201490164A1
(ru)
|
2011-06-27 |
2014-04-30 |
Новартис Аг |
Твердые формы и соли производных тетрагидропиридопиримидина
|
|
ITMI20111309A1
(it)
|
2011-07-14 |
2013-01-15 |
Italiana Sint Spa |
Procedimento di preparazione di imatinib mesilato
|
|
CN102321070B
(zh)
*
|
2011-07-27 |
2013-05-22 |
江苏先声药物研究有限公司 |
反溶剂重结晶法制备伊玛替尼甲烷磺酸盐α晶型
|
|
ES2691650T3
(es)
|
2011-09-15 |
2018-11-28 |
Novartis Ag |
3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como inhibidores de tirosina quinasa c-Met
|
|
BR112014009993A2
(pt)
|
2011-10-28 |
2017-04-25 |
Novartis Ag |
método para o tratamento de tumores do estroma gastrointestinal
|
|
WO2013063003A1
(en)
|
2011-10-28 |
2013-05-02 |
Novartis Ag |
Method of treating gastrointestinal stromal tumors
|
|
US9707231B2
(en)
|
2011-11-01 |
2017-07-18 |
Modgene, Llc |
Compositions and methods for reduction of amyloid-beta load
|
|
EP2785717B1
(en)
|
2011-11-29 |
2016-01-13 |
Novartis AG |
Pyrazolopyrrolidine compounds
|
|
US9408885B2
(en)
|
2011-12-01 |
2016-08-09 |
Vib Vzw |
Combinations of therapeutic agents for treating melanoma
|
|
EP2604596A1
(en)
|
2011-12-16 |
2013-06-19 |
Deva Holding Anonim Sirketi |
Polymorphs of imatinib
|
|
PL2794600T3
(pl)
|
2011-12-22 |
2018-06-29 |
Novartis Ag |
Pochodne 2,3-dihydro-benzo[1,4]oksazyny i powiązane związki jako inhibitory kinazy fosfoinozytydu-3 (PI3K) do leczenia np. reumatoidalnego zapalenia stawów
|
|
EP2794594A1
(en)
|
2011-12-22 |
2014-10-29 |
Novartis AG |
Quinoline derivatives
|
|
US9126979B2
(en)
|
2011-12-23 |
2015-09-08 |
Novartis Ag |
Compounds for inhibiting the interaction of BCL2 with binding partners
|
|
US20130178520A1
(en)
|
2011-12-23 |
2013-07-11 |
Duke University |
Methods of treatment using arylcyclopropylamine compounds
|
|
CN104136428A
(zh)
|
2011-12-23 |
2014-11-05 |
诺华股份有限公司 |
用于抑制bcl2与结合配偶体相互作用的化合物
|
|
KR20140107573A
(ko)
|
2011-12-23 |
2014-09-04 |
노파르티스 아게 |
Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물
|
|
US20140357633A1
(en)
|
2011-12-23 |
2014-12-04 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
|
EA201491265A1
(ru)
|
2011-12-23 |
2014-11-28 |
Новартис Аг |
Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию
|
|
PL226174B1
(pl)
|
2011-12-30 |
2017-06-30 |
Inst Farm |
Polaczenie analogu witaminy D z imatinibem do stosowania w leczeniu skojarzonym niedrobnokomorkowego raka pluc
|
|
US8815926B2
(en)
|
2012-01-26 |
2014-08-26 |
Novartis Ag |
Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
|
|
AU2013223749A1
(en)
|
2012-02-21 |
2014-09-11 |
Sun Pharmaceutical Industries Limited |
Stable dosage forms of imatinib mesylate
|
|
CN102617549A
(zh)
*
|
2012-03-02 |
2012-08-01 |
瑞阳制药有限公司 |
甲磺酸伊马替尼β晶型的制备方法
|
|
WO2013136141A1
(en)
|
2012-03-13 |
2013-09-19 |
Fresenius Kabi Oncology Ltd. |
An improved process for the preparation of alpha form of imatinib mesylate
|
|
GB201204810D0
(en)
|
2012-03-20 |
2012-05-02 |
Pharos Pharmaceutical Oriented Services Ltd |
Pharmaceutical compositions
|
|
US20150297604A1
(en)
|
2012-04-03 |
2015-10-22 |
Novartis Ag |
Combination Products with Tyrosine Kinase Inhibitors and their Use
|
|
CN102633775B
(zh)
*
|
2012-04-06 |
2013-07-17 |
江南大学 |
一种甲磺酸伊马替尼α晶型的制备方法
|
|
CN102617552A
(zh)
*
|
2012-04-06 |
2012-08-01 |
江南大学 |
一种制备α晶型甲磺酸伊马替尼的结晶方法
|
|
JP2013216644A
(ja)
*
|
2012-04-11 |
2013-10-24 |
Takada Seiyaku Kk |
イマチニブメシル酸塩経口投与製剤
|
|
WO2013169401A1
(en)
|
2012-05-05 |
2013-11-14 |
Ariad Pharmaceuticals, Inc. |
Compounds for inhibiting cell proliferation in egfr-driven cancers
|
|
JP6171003B2
(ja)
|
2012-05-24 |
2017-07-26 |
ノバルティス アーゲー |
ピロロピロリジノン化合物
|
|
WO2013188763A1
(en)
|
2012-06-15 |
2013-12-19 |
The Brigham And Women's Hospital, Inc. |
Compositions for treating cancer and methods for making the same
|
|
CA2877030A1
(en)
|
2012-06-22 |
2013-12-27 |
Basf Se |
Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers
|
|
KR101242955B1
(ko)
*
|
2012-06-25 |
2013-03-12 |
제일약품주식회사 |
이마티닙 메실레이트 결정형 α의 제조 방법
|
|
CA2878251A1
(en)
|
2012-07-11 |
2014-01-16 |
Novartis Ag |
Method of treating gastrointestinal stromal tumors
|
|
WO2014016848A2
(en)
|
2012-07-24 |
2014-01-30 |
Laurus Labs Private Limited |
Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof
|
|
ES2656091T3
(es)
|
2012-07-27 |
2018-02-23 |
Izumi Technology, Llc. |
Composiciones de inhibidores de eflujo y métodos de tratamiento que las utilizan
|
|
CN103570677B
(zh)
*
|
2012-08-02 |
2017-03-01 |
广东东阳光药业有限公司 |
一种α晶型甲磺酸伊马替尼的制备方法
|
|
US9738643B2
(en)
|
2012-08-06 |
2017-08-22 |
Duke University |
Substituted indazoles for targeting Hsp90
|
|
WO2014041551A1
(en)
|
2012-09-14 |
2014-03-20 |
Natco Pharma Limited |
Formulation comprising imatinib as oral solution
|
|
JP2015531355A
(ja)
|
2012-09-28 |
2015-11-02 |
ハンジョウ ベンシェン ファーマシューティカル シーオー．， エルティーディー．Ｈａｎｇｚｈｏｕ Ｂｅｎｓｈｅｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． |
腫瘍治療のための薬剤組成物及びその適用
|
|
US9439903B2
(en)
|
2012-10-25 |
2016-09-13 |
Cadila Healthcare Limited |
Process for the preparation of amorphous imatinib mesylate
|
|
CN105377288B
(zh)
|
2012-11-05 |
2019-11-15 |
达纳-法伯癌症研究所股份有限公司 |
Xbp1、cd138和cs1肽的组合物制备药物的用途
|
|
TW201422625A
(zh)
|
2012-11-26 |
2014-06-16 |
Novartis Ag |
二氫－吡啶并－□衍生物之固體形式
|
|
EP2749269A1
(en)
|
2012-12-31 |
2014-07-02 |
Deva Holding Anonim Sirketi |
Process for the preparation of adsorbates of imatinib
|
|
EP2749271A1
(en)
|
2012-12-31 |
2014-07-02 |
Deva Holding Anonim Sirketi |
Optimized manufacturing method and pharmaceutical formulation of imatinib
|
|
EP2749557A1
(en)
|
2012-12-31 |
2014-07-02 |
Deva Holding Anonim Sirketi |
Process for preparation of alpha polymorph of imatinib mesylate from IPA and THF solvate forms of imatinib mesylate
|
|
EP2948453B1
(en)
|
2013-01-22 |
2017-08-02 |
Novartis AG |
Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
|
|
US9403827B2
(en)
|
2013-01-22 |
2016-08-02 |
Novartis Ag |
Substituted purinone compounds
|
|
US9394368B2
(en)
|
2013-02-20 |
2016-07-19 |
Novartis Ag |
Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor
|
|
WO2014128612A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Quinazolin-4-one derivatives
|
|
CA2906542A1
(en)
|
2013-03-15 |
2014-09-25 |
Intellikine, Llc |
Combination of kinase inhibitors and uses thereof
|
|
GB201304699D0
(en)
|
2013-03-15 |
2013-05-01 |
Remedica Ltd |
Pharmaceutical compositions
|
|
WO2014155268A2
(en)
|
2013-03-25 |
2014-10-02 |
Novartis Ag |
Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
|
|
US9611283B1
(en)
|
2013-04-10 |
2017-04-04 |
Ariad Pharmaceuticals, Inc. |
Methods for inhibiting cell proliferation in ALK-driven cancers
|
|
EP2803353B1
(en)
|
2013-05-14 |
2018-05-23 |
Hetero Research Foundation |
Compositions of Imatinib
|
|
US20150018376A1
(en)
|
2013-05-17 |
2015-01-15 |
Novartis Ag |
Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
|
|
UY35675A
(es)
|
2013-07-24 |
2015-02-27 |
Novartis Ag |
Derivados sustituidos de quinazolin-4-ona
|
|
US20150044288A1
(en)
|
2013-07-31 |
2015-02-12 |
Windward Pharma, Inc. |
Aerosol tyrosine kinase inhibitor compounds and uses thereof
|
|
WO2015022664A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
|
WO2015022663A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
|
WO2015042078A2
(en)
|
2013-09-22 |
2015-03-26 |
Calitor Sciences, Llc |
Substituted aminopyrimidine compounds and methods of use
|
|
ES2748213T3
(es)
|
2013-10-17 |
2020-03-13 |
Sartar Therapeutics Ltd |
Composiciones que comprenden inhibidores de la fosfodiesterasa para su uso en el tratamiento de un tumor sólido en un paciente humano
|
|
US9636340B2
(en)
|
2013-11-12 |
2017-05-02 |
Ayyappan K. Rajasekaran |
Kinase inhibitors
|
|
TW201605450A
(zh)
|
2013-12-03 |
2016-02-16 |
諾華公司 |
Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
|
|
WO2015110949A1
(en)
|
2014-01-22 |
2015-07-30 |
Novartis Ag |
Imatinib as cholesterol decreasing agent
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
CN103800671B
(zh)
*
|
2014-02-11 |
2016-02-10 |
王思成 |
一种治疗阿弗他溃疡的中药制剂
|
|
KR20240110004A
(ko)
|
2014-03-14 |
2024-07-12 |
노파르티스 아게 |
Lag-3에 대한 항체 분자 및 그의 용도
|
|
US10000469B2
(en)
|
2014-03-25 |
2018-06-19 |
Duke University |
Heat shock protein 70 (hsp-70) receptor ligands
|
|
WO2015145388A2
(en)
|
2014-03-27 |
2015-10-01 |
Novartis Ag |
Methods of treating colorectal cancers harboring upstream wnt pathway mutations
|
|
EP3122729A4
(en)
|
2014-03-28 |
2017-11-15 |
Calitor Sciences, LLC |
Substituted heteroaryl compounds and methods of use
|
|
BR112016022499A2
(pt)
|
2014-04-03 |
2017-08-15 |
Invictus Oncology Pvt Ltd |
Produtos terapêuticos combinatórios supramoleculares
|
|
EP2927223B1
(en)
|
2014-04-04 |
2016-06-29 |
F.I.S.- Fabbrica Italiana Sintetici S.p.A. |
Process for preparing imatinib and salts thereof, free of genotoxic impurity f
|
|
CN104974133B
(zh)
*
|
2014-04-09 |
2018-04-27 |
石药集团中奇制药技术（石家庄）有限公司 |
一种甲磺酸伊马替尼晶型及其制备方法
|
|
CN104055745A
(zh)
*
|
2014-06-11 |
2014-09-24 |
连云港杰瑞药业有限公司 |
一种甲磺酸伊马替尼片的制备方法
|
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
|
BR112017001695A2
(pt)
|
2014-07-31 |
2017-11-21 |
Novartis Ag |
terapia de combinação
|
|
ES2926687T3
(es)
|
2014-08-28 |
2022-10-27 |
Eisai R&D Man Co Ltd |
Derivado de quinolina muy puro y método para su producción
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
US9988452B2
(en)
|
2014-10-14 |
2018-06-05 |
Novartis Ag |
Antibody molecules to PD-L1 and uses thereof
|
|
PT3209647T
(pt)
|
2014-10-21 |
2020-09-10 |
Ariad Pharma Inc |
Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidino-2,4-diamina
|
|
EP3233918A1
(en)
|
2014-12-19 |
2017-10-25 |
Novartis AG |
Combination therapies
|
|
PL3263106T3
(pl)
|
2015-02-25 |
2024-04-02 |
Eisai R&D Management Co., Ltd. |
Sposób tłumienia goryczy pochodnej chinoliny
|
|
WO2016140717A1
(en)
|
2015-03-04 |
2016-09-09 |
Merck Sharp & Dohme Corp. |
Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
|
|
JO3746B1
(ar)
|
2015-03-10 |
2021-01-31 |
Aduro Biotech Inc |
تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون"
|
|
CN104817536A
(zh)
*
|
2015-04-14 |
2015-08-05 |
江苏豪森药业股份有限公司 |
适合药用的甲磺酸伊马替尼非针状α晶型及其制备方法
|
|
ES2886107T3
(es)
|
2015-06-16 |
2021-12-16 |
Prism Biolab Co Ltd |
Antineoplásico
|
|
DK3317301T3
(da)
|
2015-07-29 |
2021-06-28 |
Immutep Sas |
Kombinationsterapier omfattende antistofmolekyler mod lag-3
|
|
US20180207273A1
(en)
|
2015-07-29 |
2018-07-26 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
|
CN108025051B
(zh)
|
2015-07-29 |
2021-12-24 |
诺华股份有限公司 |
包含抗pd-1抗体分子的联合疗法
|
|
EP3347097B1
(en)
|
2015-09-11 |
2021-02-24 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
|
|
TWI772275B
(zh)
|
2015-11-03 |
2022-08-01 |
美商健生生物科技公司 |
特異性結合pd-1、tim-3或pd-1與tim-3之抗體及其用途
|
|
WO2017078647A1
(en)
|
2015-11-05 |
2017-05-11 |
Koçak Farma Ilaç Ve Kimya Sanayi Anonim Şirketi |
Pharmaceutical compositions of imatinib
|
|
CN105503825B
(zh)
*
|
2015-12-16 |
2019-01-11 |
齐鲁天和惠世制药有限公司 |
一种甲磺酸伊马替尼β晶型的制备方法
|
|
JP2019503349A
(ja)
|
2015-12-17 |
2019-02-07 |
ノバルティス アーゲー |
Ｐｄ−１に対する抗体分子およびその使用
|
|
US10836745B2
(en)
|
2015-12-24 |
2020-11-17 |
Takeda Pharmaceutical Company Limited |
Cocrystal, production method thereof, and medicament containing cocrystal
|
|
WO2017129624A1
(en)
|
2016-01-25 |
2017-08-03 |
Krka, D.D., Novo Mesto |
Fast dispersible pharmaceutical composition comprising tyrosine-kinase inhibitor
|
|
SI3240538T1
(sl)
|
2016-03-25 |
2022-02-28 |
Ab Science |
Uporaba masitiniba za zdravljenje subpopulacije bolnikov z amiotrofično lateralno sklerozo
|
|
WO2017184956A1
(en)
|
2016-04-22 |
2017-10-26 |
Duke University |
Compounds and methods for targeting hsp90
|
|
EP3257499A1
(en)
|
2016-06-17 |
2017-12-20 |
Vipharm S.A. |
Process for preparation of imatinib methanesulfonate capsules
|
|
WO2018009466A1
(en)
|
2016-07-05 |
2018-01-11 |
Aduro Biotech, Inc. |
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
|
WO2018039203A1
(en)
|
2016-08-23 |
2018-03-01 |
Oncopep, Inc. |
Peptide vaccines and durvalumab for treating multiple myeloma
|
|
US20190209669A1
(en)
|
2016-08-23 |
2019-07-11 |
Oncopep, Inc. |
Peptide vaccines and durvalumab for treating breast cancer
|
|
EP3519441B1
(en)
|
2016-09-27 |
2022-03-30 |
Cero Therapeutics, Inc. |
Chimeric engulfment receptor molecules
|
|
US10927083B2
(en)
|
2016-09-29 |
2021-02-23 |
Duke University |
Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase
|
|
US10207998B2
(en)
|
2016-09-29 |
2019-02-19 |
Duke University |
Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
|
|
JP6691971B2
(ja)
|
2016-10-17 |
2020-05-13 |
Ｄｅｌｔａ−Ｆｌｙ Ｐｈａｒｍａ株式会社 |
慢性骨髄性白血病を治療又は寛解するための医薬組成物
|
|
PL3539138T3
(pl)
|
2016-11-11 |
2021-12-13 |
Curium Us Llc |
Sposoby generowania germanu-68 ze zmniejszoną ilością części lotnych
|
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
|
US20200172628A1
(en)
|
2017-06-22 |
2020-06-04 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
CN111386284A
(zh)
|
2017-09-26 |
2020-07-07 |
森罗治疗公司 |
嵌合吞噬受体分子和使用方法
|
|
WO2019083960A1
(en)
|
2017-10-24 |
2019-05-02 |
Oncopep, Inc. |
PEPTIDE VACCINES AND HDAC INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA
|
|
US20200276304A1
(en)
|
2017-10-24 |
2020-09-03 |
Oncopep, Inc. |
Peptide vaccines and pembrolizumab for treating breast cancer
|
|
EP3710006A4
(en)
|
2017-11-19 |
2021-09-01 |
Sunshine Lake Pharma Co., Ltd. |
SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR METHODS OF USE
|
|
JP7021356B2
(ja)
|
2017-12-21 |
2022-02-16 |
ヘフェイ インスティテューツ オブ フィジカル サイエンス， チャイニーズ アカデミー オブ サイエンシーズ |
ピリミジン誘導体系キナーゼ阻害剤類
|
|
CA3083040A1
(en)
|
2018-01-20 |
2019-07-25 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
|
JP2021519580A
(ja)
|
2018-03-28 |
2021-08-12 |
セロ・セラピューティクス・インコーポレイテッドＣＥＲＯ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． |
キメラ貪食受容体のための発現ベクター、遺伝子改変宿主細胞およびそれらの使用
|
|
WO2019191334A1
(en)
|
2018-03-28 |
2019-10-03 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
|
MX2020010241A
(es)
|
2018-03-28 |
2020-10-16 |
Cero Therapeutics Inc |
Composiciones de inmunoterapia celular y usos de las mismas.
|
|
UY38247A
(es)
|
2018-05-30 |
2019-12-31 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
|
WO2020023628A1
(en)
|
2018-07-24 |
2020-01-30 |
Hygia Pharmaceuticals, Llc |
Compounds, derivatives, and analogs for cancer
|
|
SG11202106635WA
(en)
|
2018-12-21 |
2021-07-29 |
Daiichi Sankyo Co Ltd |
Combination of antibody-drug conjugate and kinase inhibitor
|
|
CA3149796A1
(en)
|
2019-08-02 |
2021-02-11 |
Onehealthcompany, Inc. |
Anti-cancer agents for the treatment of canine cancers
|
|
WO2021053559A1
(en)
|
2019-09-18 |
2021-03-25 |
Novartis Ag |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
|
US20240058446A1
(en)
|
2019-10-03 |
2024-02-22 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
|
US20220395553A1
(en)
|
2019-11-14 |
2022-12-15 |
Cohbar, Inc. |
Cxcr4 antagonist peptides
|
|
WO2021233534A1
(en)
|
2020-05-20 |
2021-11-25 |
Pvac Medical Technologies Ltd |
Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
|
|
WO2021185844A1
(en)
|
2020-03-16 |
2021-09-23 |
Pvac Medical Technologies Ltd |
Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
|
|
US20230285576A1
(en)
|
2020-08-05 |
2023-09-14 |
Ellipses Pharma Ltd |
Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
|
|
WO2022036265A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Chimeric tim receptors and uses thereof
|
|
WO2022036287A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Anti-cd72 chimeric receptors and uses thereof
|
|
WO2022036285A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase
|
|
WO2022047259A1
(en)
|
2020-08-28 |
2022-03-03 |
California Institute Of Technology |
Synthetic mammalian signaling circuits for robust cell population control
|
|
TW202237638A
(zh)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
|
|
BR112023017213A2
(pt)
|
2021-02-26 |
2023-11-21 |
Kelonia Therapeutics Inc |
Vetores lentivirais direcionados a linfócitos
|
|
WO2023010097A1
(en)
|
2021-07-28 |
2023-02-02 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
|
CN114957206B
(zh)
*
|
2022-04-11 |
2024-02-27 |
中国药科大学 |
伊马替尼共晶及其制备方法
|
|
WO2024030441A1
(en)
|
2022-08-02 |
2024-02-08 |
National University Corporation Hokkaido University |
Methods of improving cellular therapy with organelle complexes
|